BPC-157 Subcutaneous Research Dosing Protocol

[Randy]

For research use only. Not medical advice.

Overview

BPC-157 is a synthetic 15–amino-acid peptide studied for potential effects on tissue repair, inflammation modulation, and gastrointestinal protection.
Human clinical evidence is still limited, so researchers rely on conservative dosing patterns derived from preclinical data.
Subcutaneous administration is the most common route in systemic research models.

Daily Dosing Protocol (Subcutaneous)

Standard Daily Range

200–600 mcg once daily

Escalate gradually to assess individual response and tolerance.

Titration Schedule

Weeks 1–2

200 mcg daily

Useful as a gentle introduction, particularly when monitoring sensitivity.

Weeks 3–4

400 mcg daily

Represents the common working dose for generalized healing or recovery-focused protocols.

Weeks 5–8+

600 mcg daily

Higher end of typical daily research use; often maintained for prolonged tissue-repair goals.

Timing

Once daily, at any consistent time.

Some researchers prefer morning fasted dosing; others use evening to complement recovery protocols — timing is flexible.

Cycle Length

Standard BPC-157 research cycles:

4–8 weeks, depending on the model

Optional 2–4 week break before repeating

Shorter cycles may be used for acute-injury research models

Chronic continuous use is less common due to limited long-term human data.

Common Research Notes

BPC-157 is generally well tolerated, though individual sensitivity varies.

Some subjects report improvements in soft-tissue recovery, joint comfort, or GI stability within 1–3 weeks.

Effects may plateau after several weeks, which is why cycles often cap at 8 weeks.

Some researchers combine BPC-157 with TB-500 or GHK-Cu for injury-specific protocols.